Keyword Analysis & Research: genelux
Keyword Research: People who searched genelux also searched
Search Results related to genelux on Search Engine
-
Genelux Corporation | Redefining Immuno-Oncology
https://genelux.com/
WEBGenelux Corporation is a biotechnology company that develops oncolytic immunotherapy products based on the oncolytic vaccinia virus (VACV) platform. Olvi-Vec is their lead …
DA: 21 PA: 9 MOZ Rank: 81
-
Genelux Corporation | Pipeline
https://genelux.com/overview/
WEBOverview. We are dedicated to developing a pipeline of next-generation immunotherapies for patients suffering with aggressive and/or difficult-to-treat solid tumor types. Information about our investigational products …
DA: 61 PA: 21 MOZ Rank: 18
-
Genelux Corporation (GNLX) - Yahoo Finance
https://finance.yahoo.com/quote/GNLX
WEBGenelux Corporation (GNLX) Follow. 4.1200 -0.1600 (-3.74%) At close: April 12 at 4:00 PM EDT. Mountain. Loading Chart for GNLX. 9/21 12:03 PM. DELL. Find the latest Genelux … Ask: 4.9600 x 100 Open: 5.0000 Bid: 3.4300 x 100 Previous Close: 4.9300
Ask: 4.9600 x 100
Open: 5.0000
Bid: 3.4300 x 100
Previous Close: 4.9300
DA: 27 PA: 31 MOZ Rank: 76
-
Genelux Corporation | Technology
https://genelux.com/our-science/
WEBGenelux is a biotechnology company that develops oncolytic immunotherapy drug candidates based on the use of viruses that selectively kill cancer cells. Learn about …
DA: 63 PA: 16 MOZ Rank: 17
-
Genelux Corporation | News Releases
https://investors.genelux.com/news-events/news-releases
WEBSep 14, 2023 · WESTLAKE VILLAGE, Calif. , Aug. 02, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology …
DA: 57 PA: 55 MOZ Rank: 40
-
Genelux Corporation | Our Program
https://genelux.com/our-program/
WEBGenelux Corporation is committed to developing safe and effective next-generation immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid …
DA: 64 PA: 11 MOZ Rank: 13
-
Genelux Corporation | Genelux Corporation Receives FDA Fast …
https://investors.genelux.com/news-releases/news-release-details/genelux-corporation-receives-fda-fast-track-designation-olvi-vec
WEBNov 27, 2023 · Genelux Corporation, a late clinical-stage immuno-oncology company, announced that the FDA has granted Fast Track designation for the development …
DA: 72 PA: 89 MOZ Rank: 93
-
Genelux Corporation - Wikipedia
https://en.wikipedia.org/wiki/Genelux_Corporation
WEBU.S. Products. Olvi-Vec. Website. www.genelux.com. Genelux Corporation is a late clinical-stage public company (Nasdaq: GNLX) developing a pipeline of next-generation …
DA: 63 PA: 8 MOZ Rank: 7
-
Genelux Corporation Announces Publication of Positive
https://www.globenewswire.com/news-release/2023/05/25/2676691/0/en/Genelux-Corporation-Announces-Publication-of-Positive-Topline-Data-from-Phase-2-VIRO-15-Trial-Evaluating-Olvimulogene-Nanivacirepvec-Olvi-Vec-in-Platinum-Resistant-or-Refractory-Ov.html
WEBMay 25, 2023 · WESTLAKE VILLAGE, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology …
DA: 85 PA: 50 MOZ Rank: 42
-
Genelux Corporation Receives FDA Fast Track Designation for
https://www.globenewswire.com/news-release/2023/11/27/2786017/0/en/Genelux-Corporation-Receives-FDA-Fast-Track-Designation-for-Olvi-Vec-in-Platinum-Resistant-Refractory-Ovarian-Cancer.html
WEBNov 27, 2023 · WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the United States Food and Drug...
DA: 41 PA: 87 MOZ Rank: 85
